EMA Withdrawn: Rituzena (previously Tuxella) (rituximab) — Celltrion Healthcare Hungary Kft.

View source ↗

Summary

EMA withdrew Rituzena (rituximab) from the market (formerly Tuxella), with the decision dated 28 January 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Microscopic Polyangiitis
• Non-hodgkin Lymphoma
• Wegener Granulomatosis

Drugs mentioned

• Rituzena (rituximab)
• Tuxella (rituximab)

Snippet

Status: Withdrawn. Therapeutic area: Lymphoma, Non-Hodgkin;Microscopic Polyangiitis;Leukemia, Lymphocytic, Chronic, B-Cell;Wegener Granulomatosis. MAH: Celltrion Healthcare Hungary Kft.. Decision date: 28/01/2019